^
BIOMARKER:

BCR-ABL1 mutation

i
Other names: BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL, ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
Entrez ID:
BCR-ABL1 mutation
CML
ABL001
Sensitive: C2 – Inclusion Criteria
BCR-ABL1 mutation
CML
venetoclax + nilotinib
Sensitive: C3 – Early Trials
BCR-ABL1 mutation
CML
venetoclax + bosutinib
Sensitive: C3 – Early Trials
BCR-ABL1 mutation
CML
venetoclax + ponatinib
Sensitive: C3 – Early Trials
BCR-ABL1 mutation
CML
venetoclax + dasatinib
Sensitive: C3 – Early Trials
BCR-ABL1 mutation
AML
venetoclax + dasatinib
Sensitive: C3 – Early Trials
BCR-ABL1 mutation
AML
venetoclax + ponatinib
Sensitive: C3 – Early Trials
BCR-ABL1 mutation
ALL
dasatinib + blinatumomab
Sensitive: C3 – Early Trials